학술논문
Anti-CD30 CAR T cells as consolidation after autologous haematopoietic stem-cell transplantation in patients with high-risk CD30+lymphoma: a phase 1 study
Document Type
Article
Author
Grover, Natalie S; Hucks, George; Riches, Marcie L; Ivanova, Anastasia; Moore, Dominic T; Shea, Thomas C; Seegars, Mary Beth; Armistead, Paul M; Kasow, Kimberly A; Beaven, Anne W; Dittus, Christopher; Coghill, James M; Jamieson, Katarzyna J; Vincent, Benjamin G; Wood, William A; Cheng, Catherine; Morrison, Julia Kaitlin; West, John; Cavallo, Tammy; Dotti, Gianpietro; Serody, Jonathan S; Savoldo, Barbara
Source
The Lancet Haematology; May 2024, Vol. 11 Issue: 5 pe358-e367, 10p
Subject
Language
ISSN
23523026
Abstract
Chimeric antigen receptor (CAR) T cells targeting CD30 are safe and have promising activity when preceded by lymphodepleting chemotherapy. We aimed to determine the safety of anti-CD30 CAR T cells as consolidation after autologous haematopoietic stem-cell transplantation (HSCT) in patients with CD30+lymphoma at high risk of relapse.